JNJ-678 (JNJ-53718678)

An RSV fusion inhibitor

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥550.00

440.00

- +
10mg

￥925.00

740.00

- +
25mg

￥1962.00

1570.00

- +
50mg

￥3375.00

2700.00

- +
100mg

￥5825.00

4660.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajce48836
CAS: 1383450-81-4
别名: JNJ-678; JNJ-53718678
分子式: C21H20ClF3N4O3S
分子量: 500.92
纯度: >98%
溶解度: DMSO : 65 mg/mL (129.76 mM);Water : < 0.1 mg/mL (insoluble)
储存: Store at -20°C
库存: 现货

Background

JNJ-53718678 is an inhibitor of respiratory syncytial virus (RSV) fusion.¹ JNJ-53718678 binds to and stabilizes the RSV fusion protein in its prefusion conformation.² It reduces RSV replication in RSV-infected HeLa cells (IC₅₀ = 0.5 nM) with a 50% cytotoxic concentration (CC₅₀) of greater than 50 ?M.¹ JNJ-53718678 (4-100 mg/kg), administered prior to infection, reduces RSV viral titers in lavaged-lung tissue and viral RNA production in the lungs in a semi-permissive cotton rat model of RSV.² JNJ-53718678 also reduces RSV viral titers in bronchoalveolar lavage fluid (BALF) in a fully replicative neonatal lamb model of RSV when administered at doses of 5 and 25 mg/kg per day.

1.Vendeville, S., Tahri, A., Hu, L., et al.Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a potent and orally bioavailable fusion inhibitor of respiratory syncytial virusJ. Med. Chem.63(15)8046-8058(2020) 2.Roymans, D., Alnajjar, S.S., Battles, M.B., et al.Therapeutic efficacy of a respiratory syncytial virus fusion inhibitorNat. Commun.8(1)167(2017)

Protocol

Cell experiment:

The antiviral activity of JNJ-678 (JNJ-53718678) against hMPV is evaluated using a cellular infectious assay in 96-well plates in which Vero/TMPRSS2 cells are infected with recombinant hMPV65. Cells are treated with different concentrations of JNJ-678 (JNJ-53718678) and then infected with recombinant hMPV (1×104 PFU per well). Three days post-virus exposure, viral replication is quantified by measuring fluorescence and the EC50 is calculated[1].

Animal experiment:

Rats[1]Cotton rats receive either a single dose at 24?h after viral infection or once-daily doses of 40?mg/kg JNJ-678 (JNJ-53718678) by oral gavage, at 24, 48, and 72?h after viral infection. The decrease of viral replication in all experiments is compared to challenged animals that received only the vehicle[1].

参考文献:

[1]. Roymans D, et al. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun. 2017 Aug 1;8(1):167.